Search Result

Results for "

major depressive disorder

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (12) Acyltransferase (1) Adrenergic Receptor (3) Akt (3) AMPK (3) Amyloid-β (3) Antibiotic (1) Apoptosis (3) Autophagy (3) Bacterial (3) Calcium Channel (3) COX (3) Cytochrome P450 (1) Dopamine Receptor (1) Dopamine Transporter (1) Epigenetic Reader Domain (3) ERK (3) Estrogen Receptor/ERR (1) HCN Channel (1) HDAC (1) Heme Oxygenase (HO) (1) Histamine Receptor (2) HIV (2) iGluR (5) Interleukin Related (4) Isotope-Labeled Compounds (11) Keap1-Nrf2 (1) MCHR1 (GPR24) (1) mGluR (6) MMP (3) Monoamine Oxidase (6) Monoamine Transporter (1) mTOR (8) nAChR (1) NF-κB (3) Opioid Receptor (5) Orexin Receptor (OX Receptor) (1) p38 MAPK (3) PERK (5) Phosphodiesterase (PDE) (3) PI3K (3) PKC (3) Reactive Oxygen Species (ROS) (3) Reference Standards (12) Serotonin Transporter (29) STAT (3) Thyroid Hormone Receptor (1) Trk Receptor (3)
By Research Areas:	Cancer (16) Infection (2) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (70)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Targets Recommended: MHC CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16900

Rolipram Maximum Cited Publications 19 Publications Verification (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Infection Neurological Disease Cancer
Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-B0176A

Sertraline hydrochloride 15+ Cited Publications	Serotonin Transporter	Neurological Disease Cancer
Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-B0161A

Duloxetine hydrochloride 10+ Cited Publications (S)-Duloxetine hydrochloride; LY-248686 hydrochloride	Serotonin Transporter	Neurological Disease Cancer
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-14262

Vilazodone 5+ Cited Publications EMD 68843; SB659746A	5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-14199

Selegiline hydrochloride 5+ Cited Publications Deprenyl hydrochloride; (-)-Selegiline hydrochloride; (-)-Deprenyl hydrochloride	Monoamine Oxidase	Neurological Disease
Selegiline (Deprenyl) hydrochloride is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline hydrochloride exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline hydrochloride can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-B0161

Duloxetine 10+ Cited Publications LY248686	Serotonin Transporter	Neurological Disease Cancer
Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0478A

Trazodone 5+ Cited Publications AF-1161 free base	5-HT Receptor Serotonin Transporter Histamine Receptor Adrenergic Receptor	Neurological Disease
Trazodone (AF-1161 free base) is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). Trazodone has anti-depressant and anti-insomnious activity. Trazodone exerts antagonistic properties against a1- and a2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects .

HY-122422

Gepirone	5-HT Receptor	Others
Gepirone is a selective and affinitive 5-HT_1A agonist. Gepirone binds selectively to 5-HT_1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research .

HY-B0168A

Milnacipran hydrochloride 2 Publications Verification	Serotonin Transporter PERK	Neurological Disease
Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (K_i values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-114452

LY2940094 1 Publications Verification BTRX-246040	Opioid Receptor	Neurological Disease
LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .

HY-N0735

Phellodendrine chloride 2 Publications Verification	Autophagy Apoptosis AMPK mTOR STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-16728

Rapastinel 1 Publications Verification GLYX-13	iGluR ERK mTOR	Neurological Disease Cancer
Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC₅₀=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .

HY-160207

Elunetirom MA-JD21; ABX-002	Thyroid Hormone Receptor	Neurological Disease
Elunetirom (MA-JD21 )is a TR-β selective CNS-penetrant TR-β agonist prodrug and can be used for study of major depressive disorder (MDD) .

HY-172550

MS7710	HCN Channel	Neurological Disease
MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated I_h current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .

HY-14198

Selegiline Deprenyl; (-)-Selegiline; (-)-Deprenyl	Monoamine Oxidase	Neurological Disease
Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-114452A

LY2940094 tartrate 1 Publications Verification BTRX-246040 tartrate	Opioid Receptor	Neurological Disease
LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models .

HY-109046

Tulrampator 2 Publications Verification CX-1632; S-47445	iGluR mTOR	Neurological Disease
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .

HY-157521

AANAT-IN-1	Acyltransferase	Neurological Disease Metabolic Disease
AANAT-IN-1 is an arylalkylamine N-acetyltransferase (AANAT) inhibitor with a sheep AANAT IC₅₀ of 9.9 μM. AANAT-IN-1 binds to the active site of sheep AANAT, interacting with amino acid residues via hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridges, inhibiting the enzyme's catalytic activity. AANAT-IN-1 can be used for the researches of circadian rhythm-associated neuropsychiatric conditions, seasonal affective disorder, and other diseases associated with abnormally elevated melatonin levels .

HY-N0427

Phellodendrine	Akt NF-κB AMPK mTOR PKC STAT Interleukin Related p38 MAPK COX Reactive Oxygen Species (ROS) Apoptosis Autophagy PI3K MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine is an orally active plant alkaloid. Phellodendrine inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-15413A

Edivoxetine hydrochloride LY 2216684 hydrochloride	Serotonin Transporter	Neurological Disease
Edivoxetine (LY 2216684) hydrochloride is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine hydrochloride can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .

HY-16728B

Rapastinel Trifluoroacetate 1 Publications Verification GLYX-13 Trifluoroacetate	iGluR mTOR ERK	Neurological Disease
Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC₅₀=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .

HY-120717

VU6001966	mGluR Cytochrome P450	Neurological Disease
VU6001966 is a brain-penetrant and selective mGlu2 receptor inhibitor. VU6001966 blocks mGlu2 receptor activity, counteracts LY379268 (HY-103558)-mediated blood-brain barrier protection and inflammatory cytokine dampening in microglia under inflammatory conditions. VU6001966 enhances antidepressant effects when combined with Scopolamine (HY-N0296). VU6001966 can be used for the research of major depressive disorder .

HY-19686

Ipsapirone TVX Q 7821 free base	5-HT Receptor	Neurological Disease
Ipsapirone (TVX Q 7821) is an anxiolytic compound and a 5-HT_1A receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits 5-HT_1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT₂ and the α₁-adrenergic function .

HY-B0176AR

Sertraline hydrochloride (Standard)	Reference Standards Serotonin Transporter	Neurological Disease Cancer
Sertraline (hydrochloride) (Standard) is the analytical standard of Sertraline (hydrochloride). This product is intended for research and analytical applications. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-B0168

Milnacipran 2 Publications Verification	Serotonin Transporter PERK	Neurological Disease
Milnacipran is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (K_i values of 31 and 8.5 nM, respectively). Milnacipran inhibits pERK1/2 activation. Milnacipran has antidepressant, anxiolytic and analgesic properties. Milnacipran inhibits biting behavior in mice. Milnacipran can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .

HY-B0161S

Duloxetine-d7	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
Duloxetine-d₇ ((S)-Duloxetine-d₇) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0176AS

rel-Sertraline-d3 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
rel-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-W039283

MCH-1 antagonist 2	MCHR1 (GPR24)	Neurological Disease Cancer
MCH-1 antagonist 2 (l-BROMO-2,4-DIFLUORO-5-NITROBEN-ZENE) is a melanin concentrating hormone-1 (MCH1) receptor-selective 4-aryl piperidine. MCH-1 antagonist 2 can be used for the research of depression, anxiety, obesity, urge incontinence, urinary incontinence, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, urinary frequency, urinary urgency, nocturia, enuresis, bulimia, bulimia nervosa, anorexia nervosa, major depressive disorder, dysthymic disorder, bipolar 1 and 2 disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, overactive bladder .

HY-177085

Fumiporexant	Orexin Receptor (OX Receptor)	Neurological Disease
Fumiporexant (Compound Example 93) is an orally active, brain-penetrant and selective Orexin receptor 2 (OX2R) antagonist. Fumiporexant regulates the sleep-wake cycle and emotion-related pathways in the central nervous system. Fumiporexant is promising for research of nervous system diseases such as insomnia and major depressive disorder .

HY-14262S1

Vilazodone-d8 hydrochloride EMD 68843-d8; SB659746A-d8	5-HT Receptor Serotonin Transporter Isotope-Labeled Compounds	Neurological Disease
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-B0161E

(±)-Duloxetine hydrochloride (Rac)-Duloxetine hydrochloride	Serotonin Transporter	Neurological Disease
(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .

HY-154977

ETAP	Monoamine Oxidase	Neurological Disease Cancer
ETAP is a MAO-A and MAO-B inhibitor. ETAP has antidepressant-like effect. ETAP can be used for research of major depressive disorder .

HY-B0176AS1

(±)-cis-Sertraline-d3 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
(±)-cis-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-122422A

Gepirone hydrochloride	5-HT Receptor	Neurological Disease
Gepirone is a selective 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research .

HY-15413

Edivoxetine LY 2216684	Adrenergic Receptor	Neurological Disease
Edivoxetine (LY 2216684) is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .

HY-110255

AZD 2066 1 Publications Verification	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-14262R

Vilazodone (Standard) EMD 68843 (Standard); SB659746A (Standard)	Reference Standards 5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (Standard) is the analytical standard of Vilazodone. This product is intended for research and analytical applications. Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-174395

CD-10	Keap1-Nrf2 Interleukin Related Heme Oxygenase (HO)	Neurological Disease
CD-10 is an orally active and BBB-penatrable Keap1-Nrf2 protein-protein interaction (PPI) inhibitor. CD-10 binds to Keap1 with a K_D value of 193 nM. CD-10 exhibits potent anti-oxidative and anti-inflammatory effects through Keap1-Nrf2 pathway activation, evidenced by reduced levels of MDA, IL-4, IL-10 and increased expression of HO-1. CD-10 effectively alleviated anxiety and depressive behaviors and restored serum neurotransmitter levels by promoting Nrf2 nuclear translocation in the chronic unpredictable mild stress (CUMS) mouse model. CD-10 can be used for the study of depression.

HY-B0168S

Milnacipran-d10 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter PERK	Neurological Disease
Milnacipran-d₁₀ (hydrochloride) is the deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (K_i values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .

HY-W052508R

Norquetiapine (Standard) N-Desalkylquetiapine (Standard)	5-HT Receptor Reference Standards	Neurological Disease
Norquetiapine is an antidepressant and neuroprotective agent and is the active metabolic component of Quetiapine (HY-14544). Norquetiapine is also a partial 5-HT1A receptor agonist, and a presynaptic α2, 5-HT2C and 5-HT7 b> Receptor antagonist. Norquetiapine can also selectively inhibit norepinephrine transporter (NET), inhibit norepinephrine reuptake, and has potential inhibitory effects on bipolar depression, major depressive disorder, and generalized anxiety disorder. Norquetiapine demonstrated in vivo activity in forced swimming in mice and learned helplessness tests in rats .

HY-16900R

Rolipram (Standard) (R,S)-Rolipram (Standard); (±)-Rolipram (Standard); ZK 62711 (Standard)	Reference Standards Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Cancer
Rolipram (Standard) is the analytical standard of Rolipram (HY-16900). This product is intended for research and analytical applications. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-N0735R

Phellodendrine chloride (Standard)	Reference Standards Autophagy mTOR AMPK Apoptosis STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.

HY-179063

5-HT2A receptor agonist-13	5-HT Receptor Dopamine Receptor Serotonin Transporter	Neurological Disease
5-HT2A receptor agonist-13 (Compound 28c) is a partial agonist of the 5-HT_2A receptor, with an EC₅₀ value of 416.9 nM and a K_i value of 113.9 nM. 5-HT2A receptor agonist-13 exhibits very weak agonistic activity towards the 5-HT_2B receptor (EC₅₀ = 120.2 nM), D2 receptor (K_i = 1298 nM), and has no activity towards the 5-HT_2C receptor. 5-HT2A receptor agonist-13 exhibits weak inhibitory activity on the serotonin transporter (SERT) (EC₅₀ = 977.2 nM). 5-HT2A receptor agonist-13 has antidepressant activity in mouse models and does not induce hallucinogenic behavior. 5-HT2A receptor agonist-13 can be used for the study of major depressive disorder (MDD) and treatment-resistant depression (TRD) .

HY-B0478AR

Trazodone (Standard) AF-1161 free base (Standard)	Reference Standards 5-HT Receptor Histamine Receptor Adrenergic Receptor Serotonin Transporter	Neurological Disease
Trazodone (AF-1161 free base) (Standard) is the analytical standard of Trazodone. This product is intended for research and analytical applications. Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). Trazodone has anti-depressant and anti-insomnious activity. Trazodone exerts antagonistic properties against a1- and a2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects .

HY-B0161AS

Duloxetine-d3 hydrochloride (S)-Duloxetine D3 hydrochloride; LY248686 D3 hydrochloride	Serotonin Transporter	Neurological Disease
Duloxetine-d₃ (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-19686A

Ipsapirone hydrochloride TVX Q 7821	5-HT Receptor	Neurological Disease
Ipsapirone hydrochloride (TVX Q 7821) is an anxiolytic compound and a 5-HT_1A receptor partial agonist. Ipsapirone hydrochloride (TVX Q 7821) also exhibits 5-HT_1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT₂ and the α₁-adrenergic function .

HY-113683

AZ 12488024 AZD7268	Opioid Receptor	Neurological Disease
AZ 12488024 (AZD7268) is a SNC80 (HY-101202) derivative and a δ-opioid receptor agonist. AZ 12488024 is available for research into major depressive disorder .

HY-B0161AR

Duloxetine hydrochloride (Standard) (S)-Duloxetine hydrochloride (Standard); LY-248686 hydrochloride (Standard)	Reference Standards Serotonin Transporter	Neurological Disease Cancer
Duloxetine (hydrochloride) (Standard) is the analytical standard of Duloxetine (hydrochloride). This product is intended for research and analytical applications. Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0161S3

Duloxetine-d5 oxalate (S)-Duloxetine-d5 oxalate; LY248686-d5 oxalate	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease Cancer
Duloxetine-d₅ (oxalate) ((S)-Duloxetine-d₅ (oxalate)) is deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

Cat. No.	Product Name

HY-L108

Antidepressant Compound Library

2,857 compounds

Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors.

Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent.

MCE offers a unique collection of 2,857 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Cat. No.	Product Name	Type

HY-16900G

Rolipram

Fluorescent Dyes

Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Cat. No.	Product Name	Type

HY-16900G

Rolipram

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0735

Phellodendrine chloride 2 Publications Verification	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Source Classification Cancer	Autophagy Apoptosis AMPK mTOR STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-N0427

Phellodendrine	Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Phenols Polyphenols Quinoline Alkaloids Plants Inflammation/Immunology Disease Research Fields Source Classification	Akt NF-κB AMPK mTOR PKC STAT Interleukin Related p38 MAPK COX Reactive Oxygen Species (ROS) Apoptosis Autophagy PI3K MMP
Phellodendrine is an orally active plant alkaloid. Phellodendrine inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-N0735R

Phellodendrine chloride (Standard)	Alkaloids Structural Classification Phellodendron amurense Rupr. Rutaceae Phenols Polyphenols Plants Isoquinoline Alkaloids Source Classification	Reference Standards Autophagy mTOR AMPK Apoptosis STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP
Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.

Cat. No.	Product Name	Chemical Structure

HY-B0161S

Duloxetine-d7
Duloxetine-d₇ ((S)-Duloxetine-d₇) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0176AS

rel-Sertraline-d3 hydrochloride
rel-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-14262S1

Vilazodone-d8 hydrochloride
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-B0176AS1

(±)-cis-Sertraline-d3 hydrochloride
(±)-cis-Sertraline-d₃ (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive .

HY-B0168S

Milnacipran-d10 hydrochloride

Milnacipran-d₁₀ (hydrochloride) is the deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (K_i values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .

HY-B0161AS

Duloxetine-d3 hydrochloride
Duloxetine-d₃ (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0161S3

Duloxetine-d5 oxalate
Duloxetine-d₅ (oxalate) ((S)-Duloxetine-d₅ (oxalate)) is deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-B0161ES

(±)-Duloxetine-d3 hydrochloride
(±)-Duloxetine-d₃ (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .

HY-B0161AS1

Duloxetine-d7 hydrochloride
Duloxetine-d7 hydrochloride ((S)-Duloxetine-d7 hydrochloride) is the deuterium labeled Duloxetine hydrochloride (HY-B0161A). Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .

HY-14199S

Selegiline-d5 hydrochloride

Selegiline-d₅ (hydrochloride) (Deprenyl-d₅ (hydrochloride)) is deuterium labeled Selegiline (hydrochloride). Selegiline (Deprenyl) hydrochloride is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline hydrochloride exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline hydrochloride can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-14198S

Selegiline-d5
Selegiline-d₅ (Deprenyl-d₅) is deuterium labeled Selegiline. Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

HY-B0168AS

Milnacipran-d5 hydrochloride

Milnacipran-d₅ hydrochloride is deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (K_i values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .

Cat. No.	Product Name		Classification

HY-14198B

(±)-Selegiline hydrochloride (±)-Deprenyl hydrochloride		Alkynes
(±)-Selegiline (Deprenyl) hydrochloride is the racemic of Selegiline (HY-14198). Selegiline is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder .

Targets Recommended: MHC CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16900G

Rolipram	Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Inflammation/Immunology Cancer
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

major depressive disorder

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products